What the FDA Relabeling of Abacavir Means for You and Your Patient

HLA-B*5701 Genotyping⁵

November 2008

At Mayo Medical Laboratories, the HLA-B*5701 allele typing is done by a genotyping method as described by Dr. O’Kane under the unit code 89346 with the published name HLA-B*5701 Genotype, Abacavir Hypersensitivity.

This assay is useful for predicting the likelihood of hypersensitivity reactions to abacavir in HIV-infected patients, based on the presence of the HLA-B*5701 allele and it is therefore useful to exclude these patients if they’re positive for this allele.

< Previous Slide

HLA-B*5701 Genotyping5

Next Slide >

 

Jump to section:

• Introduction
• Highly Active Antiretroviral Therapy
• Abacavir
• FDA Caution and Relabeling
• Abacavir Hypersensitivity
• Abacavir HSR and HLA Gene
• HLA-B Antigens and Alleles
• Naming Conventions - HLA-B*5701
• Chromosome 6
• Detecting HLA Alleles
• HLA-B*5701 Correlations
• HLA-B*5701 Correlations
• Clinical Utility³
• Problems
• If HSR Symptoms are Present⁴
• If HSR Symptoms are Present⁴
• Recommendations for Physicians⁵
• Recommendations for Physicians⁵
• Information for Patients⁵
• Information for Patients⁵
• HLA-B*5701 Genotyping
• References
• Questions?